WO2003050044A1 - Electrochemically activated water for the treatment of cystitis - Google Patents

Electrochemically activated water for the treatment of cystitis Download PDF

Info

Publication number
WO2003050044A1
WO2003050044A1 PCT/ZA2002/000197 ZA0200197W WO03050044A1 WO 2003050044 A1 WO2003050044 A1 WO 2003050044A1 ZA 0200197 W ZA0200197 W ZA 0200197W WO 03050044 A1 WO03050044 A1 WO 03050044A1
Authority
WO
WIPO (PCT)
Prior art keywords
aqueous
containing solution
solution
predominantly
mixed
Prior art date
Application number
PCT/ZA2002/000197
Other languages
French (fr)
Inventor
Gilbert Theo Hinze
Johannes Amos Van Der Merwe
Original Assignee
Radical Waters (Ip) (Pty) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radical Waters (Ip) (Pty) Limited filed Critical Radical Waters (Ip) (Pty) Limited
Priority to AU2002351430A priority Critical patent/AU2002351430A1/en
Publication of WO2003050044A1 publication Critical patent/WO2003050044A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
    • C02F1/46104—Devices therefor; Their operating or servicing
    • C02F1/4618—Devices therefor; Their operating or servicing for producing "ionised" acidic or basic water
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
    • C02F1/467—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction
    • C02F1/4672—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electrooxydation
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
    • C02F1/467—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction
    • C02F1/4672—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electrooxydation
    • C02F1/4674—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electrooxydation with halogen or compound of halogens, e.g. chlorine, bromine
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
    • C02F1/467—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction
    • C02F1/4676—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electroreduction
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
    • C02F1/46104—Devices therefor; Their operating or servicing
    • C02F1/46109—Electrodes
    • C02F2001/46152—Electrodes characterised by the shape or form
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
    • C02F2103/02—Non-contaminated water, e.g. for industrial water supply
    • C02F2103/026—Treating water for medical or cosmetic purposes
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2305/00—Use of specific compounds during water treatment
    • C02F2305/02—Specific form of oxidant
    • C02F2305/023—Reactive oxygen species, singlet oxygen, OH radical

Definitions

  • This invention relates to a method of and solutions for the treatment of chronic, recurrent infectious and non-specific inflammatory conditions of the urinary bladder and associated anatomical architecture.
  • any infectious condition of the urinary bladder will be associated with inflammatory changes and a concomitant hypersensitization of the bladder mucosa and/or underlying musculature, it is the progressive and ultimately chronic manifestations of the primary clinical condition that results in the irritative voiding symptoms and supra-pubic pain associated with bladder filling.
  • histological changes in the mucosal lining of the bladder, as well as underlying tissue may undergo keratinising metaplastic changes which, although non-malignant, may progress to conditions of patent malignancy unless resolved or controlled.
  • Treatment may vary from rudimentary pH modulation, i.e. urinary acidifiers to alter the internal environment suited to the bacterial populations present both in and on the bladder mucosa, through to rigorous antimicrobial therapy where the specific antimicrobial has been typed to ensure optimal efficacy against the offending microbial populations.
  • antimicrobials are selected on the basis of their specific path of urinary excretion, thus ensuring optimal concentrations of antimicrobial agents in close proximity to the sources of infection.
  • a method of treating both acute and chronic infectious cystitis including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion- containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution.
  • the electrochemically activated, aqueous solution may be selected from a group consisting of an anion-containing solution; a cation-containing solution; a mixture of an anion-containing solution and a cation-containing solution; an anion-containing solution having been prepared from an anion-containing solution, a cation-containing solution or a mixture of an anion-containing solution and a cation-containing solution; and a cation- containing solution having been prepared from an anion-containing solution, a cation- containing solution or a mixture of an anion-containing solution and a cation-containing solution.
  • the predominantly anion-containing solution is referred to hereinafter for brevity as the “anolyte solution” or “anolyte”, and the predominantly cation-containing solution is referred to as the “catholyte solution” or “catholyte”.
  • the electrochemically activated, aqueous solution may be prepared by means of electrolysis of an aqueous solution of a salt.
  • the salt may be selected from the group consisting of alkali and alkali earth metal chlorides; -carbonates; -bi-carbonates; - phosphates; -sulphates, or -nitrates; for example, sodium chloride; non-iodated sodium chloride; potassium chloride; calcium chloride; sodium carbonate; -bicarbonate; and - phosphate; potassium carbonate; -bicarbonate; and -phosphate; calcium phosphate; sodium-; -potassium; and calcium nitrate; and a mixture of at least two of the aforementioned salts.
  • the electrochemically activated, aqueous solution may be produced from a relatively low concentration aqueous salt solution.
  • the aqueous salt solution concentration may be between 0.0001% to 10%, and for some specific systems without pre-dilution of the feed, preferably between about 0.3% and 0.5% aqueous salt solution.
  • the anolyte and the catholyte may be produced by an electrochemical reactor or so- called electrolysis device, having a through flow electro-chemical cell with two co-axial cylindrical electrodes, with a tubular ceramic diaphragm located co-axially between the two electrodes so as to separate an annular inter-electrode space into a co-axial, annular catholytic and an annular anolytic chamber arrangement.
  • the electrochemical cell may have predetermined design and geometrical relationships, ensuring optimum fluid flow and re-circulation patterns.
  • the cell may have a relatively small, annular, cross-sectional total open area for fluid flow, preferably of about 180mm 2 , thus causing turbulent fluid flow there through so as to ensure maximum exposure of the solutions to the electric field.
  • the anolyte and the catholyte may be produced in the electrochemical cell under predetermined operational parameters, including a relatively low current, preferably of about 5A to 8A, and a relatively high voltage, preferably of about 6V to 48V, and more preferably between 8V and 24V, thus providing a relatively high voltage gradient or electric field intensity at the interface between the electrode surface and electrolyte, estimated to be about 10 6 V/cm.
  • the salt solution may be electrolysed to produce the anolyte and the catholyte with mixed oxidant and mixed reductant species. These species may be labile and after about 96 hours, the concentration and activity of the various activated species may reduce substantially with relatively little, alternatively no active residues remaining.
  • the anolyte solution may have a redox potential of about between +300mV and +1200mV.
  • the anolyte solution may have a pH of between 2 and 8, and preferably a pH of 7.
  • the anolyte solution may include mixed oxidant species such as CIO; CIO “ ; HCIO; OH “ ; HO 2 " ; H 2 O 2 ; O 3 ; S 2 O 8 2" and CI 2 O 6 2 .
  • the catholyte solution generally may have a pH of between 7 and 13, and preferably a pH of about 11.5, and a redox potential of between -200 mV and -1100mV and preferably of about -800mV.
  • the catholyte solution may include mixed reductant species such as OH " ; H 3 " ; O 2 ; H 2 ; HO 2 ; HO 2 " and
  • anolyte may contain organic radicals and other components such as Cl 2 , HCIO, CIO ' , CIO", Cl ⁇ HO 2 , HO 2 , O 2 , HO ⁇
  • Catholyte may contain HO ' , H 3 0 2 ⁇ 0 2 " , H0 2 " , H 2 O 2 , H 2 , HO, H 2 " ,
  • solutions has shown varying quantities of aluminium, calcium, magnesium, manganese, potassium, sodium, molybdenum, ammonium, orthophosphate, silica and chloride.
  • the varying levels of saline concentration and the mineral content of the feed water, as well as the operational variables of the electrochemical reactor, preferably the different flow rates, flow regimes, -paths and -rates of recycle, currents and potential differences, may be adjustable so as to produce anolyte and catholyte with suitable physical and chemical characteristics, with specific conductivity, redox potential and pH, concentration of "activated species" and other characteristics, for particular applications.
  • an aqueous, mixed oxidant, predominantly anion-containing solution in the treatment of acute and chronic infectious cystitis, wherein the aqueous, mixed oxidant, predominantly anion- containing solution is infused or instilled into the lumen of a urinary bladder; and wherein maximal contact between infectious microbial agents and the solution is achieved through a process of hydrodistention.
  • an aqueous, mixed oxidant, predominantly anion-containing solution in the preparation of a medicament for use in the treatment of acute and chronic infectious cystitis.
  • an aqueous, mixed oxidant, predominantly anion-containing solution in the treatment of acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture.
  • an aqueous, mixed oxidant, predominantly anion-containing solution in the preparation of a medicament for use in the treatment of acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and the associated anatomical architecture.
  • an aqueous, mixed oxidant, predominantly anion-containing solution characterised therein that it possesses distinctive anti-inflammatory properties and is suitable for use either as an instillation or as an infusate for controlling or resolving inflammatory and hyperaesthetic urine voiding symptoms and for reducing or resolving clinical haemorrhagic and histopathologic symptoms associated with repeated radiation therapies.
  • an aqueous, mixed oxidant, predominantly anion-containing solution in controlling or resolving inflammatory and hyperaesthetic urine voiding symptoms and for reducing or resolving clinical haemorrhagic and histopathologic symptoms associated with repeated radiation therapies.
  • a method of treatment of a human or animal body suffering from acute and/or chronic microbially induced cystitis including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents
  • the method may include the additional step of infusing or instilling the aqueous, mixed reductant, predominantly cation-containing solution into lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed oxidant, predominantly anion-containing solution.
  • a method of treatment of a human or animal body suffering from acute and/or chronic immunogenic and radiation induced cystitis including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation- containing solution; separating the aqueous, mixed oxidant, predominantly anion- containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed reductant, predominantly cation- containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed reductant, predominantly cation-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between the bladder
  • the method may include the additional step of infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed reductant, predominantly cation-containing solution.
  • a method of treatment of a human or animal body suffering from acute and/or chronic cystitis including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling, at a rate of approximately 150ml/hour, 2 litres of a solution comprising substantially equal parts by volume of the aqueous, mixed reductant, predominantly cation-containing solution and the aqueous, mixed oxidant, predominantly anion-containing solution and diluted to 50% strength with normal saline, into lumen of a urinary bladder of the human or animal body; and through a
  • a method of treatment of a human or animal body suffering from acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation- containing solution; separating the aqueous, mixed oxidant, predominantly anion- containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion- containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing
  • the method may include the additional step of infusing or instilling the aqueous, mixed reductant, predominantly cation-containing solution into lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed oxidant, predominantly anion-containing solution.
  • Inflammation of the bladder wall present in patients suffering from cystitis can result from one or more of three main causes, namely due to microbial infections, immunogenic causes or due to external radiation, for example during cancer treatment.
  • microbial infections namely due to microbial infections, immunogenic causes or due to external radiation, for example during cancer treatment.
  • Each of these causes of cystitis is characterised therein that is responds to specific optimal treatment methods.
  • Microbially induced cystitis responds best to treatment by anolyte which comprises anti-microbial properties
  • the immunogenic and radiation induced cystitis would respond better to treatment by catholyte, which has anti- oxidant properties and promotes healing.
  • electrochemically activated aqueous solutions as direct infusions or instillations has been shown to offer significant relief or resolution of clinical disease of the urinary bladder and associated anatomical architecture as may be associated with chronic inflammation arising from neurogenic voiding dysfunction, intractable haemorrhagic cystitis secondary to pelvic radiation therapy, and chronic recurrent cystitis of various non-specific microbial and/or inflammatory aetiologies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Electrochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hydrology & Water Resources (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental & Geological Engineering (AREA)
  • Water Supply & Treatment (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a method of treating acute and chronic infectious cystitis. The method includes the steps of electrochemically activating a dilute aqueous solution such that it includes an aqueous, mixed oxidant, predominantly anion-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution. The invention also includes a solution for treating acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture.

Description

ELECTROCHEMICALLY ACTIVATED WATER FOR THE TREATMENT OF CYSTITIS
Technical field
This invention relates to a method of and solutions for the treatment of chronic, recurrent infectious and non-specific inflammatory conditions of the urinary bladder and associated anatomical architecture.
Background art
While any infectious condition of the urinary bladder will be associated with inflammatory changes and a concomitant hypersensitization of the bladder mucosa and/or underlying musculature, it is the progressive and ultimately chronic manifestations of the primary clinical condition that results in the irritative voiding symptoms and supra-pubic pain associated with bladder filling. Aside from the overt clinical symptoms evidenced during chronic cystitis, histological changes in the mucosal lining of the bladder, as well as underlying tissue, may undergo keratinising metaplastic changes which, although non-malignant, may progress to conditions of patent malignancy unless resolved or controlled.
Long term or chronic indwelling catheterisation of quadriplegic or paraplegic patients may result in chronic or recurrent urogenital microbial infections of a primarily ascending nature. It is well established that biofilm proliferation in indwelling catheters serves as the primary focus of recurrent infection, and sub-optimal anti-microbial therapy may lead to progressive resistance to the previously efficacious therapeutic agents. Protracted microbial infections of the bladder lumen give rise to concurrent inflammatory changes in the superficial mucosal layer and thereafter also in the deeper underlying tissues and musculature. In advanced cases, chronic changes of the bladder architecture may result in patent symptoms of cystitis without any microbial agent being present and the focus of the inflammatory changes has been adjudged to be interstitial in nature. These chronic, recurrent bouts of interstitial inflammation of the urinary bladder wall and its surrounding tissue constitute a substantially hyperaesthetic and debilitating disease. The condition has been shown to be primarily associated with women, although up to 10% of cases may manifest in men.
Patients diagnosed with interstitial cystitis are limited by the variety and value of medical and surgical interventions available for the resolution of symptoms. Treatment may vary from rudimentary pH modulation, i.e. urinary acidifiers to alter the internal environment suited to the bacterial populations present both in and on the bladder mucosa, through to rigorous antimicrobial therapy where the specific antimicrobial has been typed to ensure optimal efficacy against the offending microbial populations. Similarly, antimicrobials are selected on the basis of their specific path of urinary excretion, thus ensuring optimal concentrations of antimicrobial agents in close proximity to the sources of infection.
In cases of protracted microbial infection, with a scenario of potential antimicrobial resistance developed by the microbe populations, these infections of the transitional epithelium of the bladder mucosa and the underlying musculature, may give rise to nonspecific inflammatory immunogenic conditions of the tissue. These conditions may progress to full-blown symptoms of cystitis without an infectious microbial component and have been described as being akin to a hypersensitivity reaction by the body against its own tissue types. In cases of patients receiving radiation therapy, whether generalised or specific to the pelvic region, a frequent sequel to the intervention is that of haemorrhagic cystitis, the duration and severity of which is directly dependent on the magnitude and frequency of the radiation treatment. Repeated and long-term radiation treatments have been shown to be associated with mucosal ulceration as well as telangiectatic changes of the vasculature of the bladder wall and the overt haematuria is a direct consequence of these changes.
Object of the invention It is accordingly an object of this invention to provide a more effective method for the treatment of chronic, recurrent infectious and non-specific inflammatory conditions of the urinary bladder and associated anatomical architecture that will overcome or at least minimise the above problems.
Disclosure of the invention
According to the invention there is provided a method of treating both acute and chronic infectious cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion- containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution.
The electrochemically activated, aqueous solution may be selected from a group consisting of an anion-containing solution; a cation-containing solution; a mixture of an anion-containing solution and a cation-containing solution; an anion-containing solution having been prepared from an anion-containing solution, a cation-containing solution or a mixture of an anion-containing solution and a cation-containing solution; and a cation- containing solution having been prepared from an anion-containing solution, a cation- containing solution or a mixture of an anion-containing solution and a cation-containing solution.
The predominantly anion-containing solution is referred to hereinafter for brevity as the "anolyte solution" or "anolyte", and the predominantly cation-containing solution is referred to as the "catholyte solution" or "catholyte".
The electrochemically activated, aqueous solution may be prepared by means of electrolysis of an aqueous solution of a salt. The salt may be selected from the group consisting of alkali and alkali earth metal chlorides; -carbonates; -bi-carbonates; - phosphates; -sulphates, or -nitrates; for example, sodium chloride; non-iodated sodium chloride; potassium chloride; calcium chloride; sodium carbonate; -bicarbonate; and - phosphate; potassium carbonate; -bicarbonate; and -phosphate; calcium phosphate; sodium-; -potassium; and calcium nitrate; and a mixture of at least two of the aforementioned salts. The electrochemically activated, aqueous solution may be produced from a relatively low concentration aqueous salt solution. Depending on the particular process being performed, and the method for producing the electrochemically activated solution (e.g. with or without pre-dilution of the feed solutions), the aqueous salt solution concentration may be between 0.0001% to 10%, and for some specific systems without pre-dilution of the feed, preferably between about 0.3% and 0.5% aqueous salt solution.
The anolyte and the catholyte may be produced by an electrochemical reactor or so- called electrolysis device, having a through flow electro-chemical cell with two co-axial cylindrical electrodes, with a tubular ceramic diaphragm located co-axially between the two electrodes so as to separate an annular inter-electrode space into a co-axial, annular catholytic and an annular anolytic chamber arrangement. The electrochemical cell may have predetermined design and geometrical relationships, ensuring optimum fluid flow and re-circulation patterns. The cell may have a relatively small, annular, cross-sectional total open area for fluid flow, preferably of about 180mm2, thus causing turbulent fluid flow there through so as to ensure maximum exposure of the solutions to the electric field.
The anolyte and the catholyte may be produced in the electrochemical cell under predetermined operational parameters, including a relatively low current, preferably of about 5A to 8A, and a relatively high voltage, preferably of about 6V to 48V, and more preferably between 8V and 24V, thus providing a relatively high voltage gradient or electric field intensity at the interface between the electrode surface and electrolyte, estimated to be about 106 V/cm. The salt solution may be electrolysed to produce the anolyte and the catholyte with mixed oxidant and mixed reductant species. These species may be labile and after about 96 hours, the concentration and activity of the various activated species may reduce substantially with relatively little, alternatively no active residues remaining.
The anolyte solution may have a redox potential of about between +300mV and +1200mV. The anolyte solution may have a pH of between 2 and 8, and preferably a pH of 7. Depending on the salt(s) in the feed stream used in the activation process, the anolyte solution may include mixed oxidant species such as CIO; CIO"; HCIO; OH"; HO2 " ; H2O2; O3; S2O8 2" and CI2O6 2.
The catholyte solution generally may have a pH of between 7 and 13, and preferably a pH of about 11.5, and a redox potential of between -200 mV and -1100mV and preferably of about -800mV. Depending on the salt(s) in the feed stream, the catholyte solution may include mixed reductant species such as OH"; H3 "; O2; H2 ; HO2 ; HO2 " and
Depending on the source of the water and the salt used, anolyte may contain organic radicals and other components such as Cl2, HCIO, CIO', CIO", Cl\ HO2, HO2 , O2, HO\
O3> 02 ", 3O2, 02, O", H3O+, Cϊ, H\ H2O2, Cl20, CI02\ HCI, CI2O7, S2O8 2", C2O6 2", HCIO,
H2SO4, and HS03CI. Catholyte may contain HO', H302\ 02 ", H02 ", H2O2, H2, HO, H2 ",
NaOH, KOH, Ca(OH)2 and Mg(OH)2. Analysis of the inorganic components of these
solutions has shown varying quantities of aluminium, calcium, magnesium, manganese, potassium, sodium, molybdenum, ammonium, orthophosphate, silica and chloride. The varying levels of saline concentration and the mineral content of the feed water, as well as the operational variables of the electrochemical reactor, preferably the different flow rates, flow regimes, -paths and -rates of recycle, currents and potential differences, may be adjustable so as to produce anolyte and catholyte with suitable physical and chemical characteristics, with specific conductivity, redox potential and pH, concentration of "activated species" and other characteristics, for particular applications.
According to another aspect of the invention there is provided the use of an aqueous, mixed oxidant, predominantly anion-containing solution in the treatment of acute and chronic infectious cystitis, wherein the aqueous, mixed oxidant, predominantly anion- containing solution is infused or instilled into the lumen of a urinary bladder; and wherein maximal contact between infectious microbial agents and the solution is achieved through a process of hydrodistention.
According to another aspect of the invention there is provided the use of an aqueous, mixed oxidant, predominantly anion-containing solution in the preparation of a medicament for use in the treatment of acute and chronic infectious cystitis.
According to a further aspect of the invention there is provided the use of an aqueous, mixed oxidant, predominantly anion-containing solution in the treatment of acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture.
According to another aspect of the invention there is provided the use of an aqueous, mixed oxidant, predominantly anion-containing solution in the preparation of a medicament for use in the treatment of acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and the associated anatomical architecture.
According to yet a further aspect of the invention there is provided an aqueous, mixed oxidant, predominantly anion-containing solution characterised therein that it possesses distinctive anti-inflammatory properties and is suitable for use either as an instillation or as an infusate for controlling or resolving inflammatory and hyperaesthetic urine voiding symptoms and for reducing or resolving clinical haemorrhagic and histopathologic symptoms associated with repeated radiation therapies.
According to yet a further aspect of the invention there is provided the use of an aqueous, mixed oxidant, predominantly anion-containing solution in controlling or resolving inflammatory and hyperaesthetic urine voiding symptoms and for reducing or resolving clinical haemorrhagic and histopathologic symptoms associated with repeated radiation therapies.
According to yet a further aspect of the invention there is provided a method of treatment of a human or animal body suffering from acute and/or chronic microbially induced cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution.
The method may include the additional step of infusing or instilling the aqueous, mixed reductant, predominantly cation-containing solution into lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed oxidant, predominantly anion-containing solution.
According to yet a further aspect of the invention there is provided a method of treatment of a human or animal body suffering from acute and/or chronic immunogenic and radiation induced cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation- containing solution; separating the aqueous, mixed oxidant, predominantly anion- containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed reductant, predominantly cation- containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed reductant, predominantly cation-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between the bladder wall and the solution.
The method may include the additional step of infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed reductant, predominantly cation-containing solution.
According to yet a further aspect of the invention there is provided a method of treatment of a human or animal body suffering from acute and/or chronic cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling, at a rate of approximately 150ml/hour, 2 litres of a solution comprising substantially equal parts by volume of the aqueous, mixed reductant, predominantly cation-containing solution and the aqueous, mixed oxidant, predominantly anion-containing solution and diluted to 50% strength with normal saline, into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed solution and the entire bladder mucosal surface so as to ensure maximal contact between the bladder wall and any associated infectious microbial agents, and the solution.
According to yet a further aspect of the invention there is provided a method of treatment of a human or animal body suffering from acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation- containing solution; separating the aqueous, mixed oxidant, predominantly anion- containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion- containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution.
The method may include the additional step of infusing or instilling the aqueous, mixed reductant, predominantly cation-containing solution into lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed oxidant, predominantly anion-containing solution.
Specific embodiment of the invention
Experiments were conducted on patients with intractable and recurrent interstitial cystitis that had proven to be refractory to all current and traditional means of therapeutic intervention.
Inflammation of the bladder wall present in patients suffering from cystitis can result from one or more of three main causes, namely due to microbial infections, immunogenic causes or due to external radiation, for example during cancer treatment. Each of these causes of cystitis is characterised therein that is responds to specific optimal treatment methods. Microbially induced cystitis responds best to treatment by anolyte which comprises anti-microbial properties, whereas the immunogenic and radiation induced cystitis would respond better to treatment by catholyte, which has anti- oxidant properties and promotes healing.
However, the applicant has found that although anolyte treatment is sufficient in microbially induced cystitis, and catholyte in immunogenic and radiation induced cystitis, treatment of patients with the other one of the two solutions (catholyte or anolyte, as the case may be) in both cases have increased recovery. It is believed that this is so because of the following reasons. After the causative microbes have been eradicated by treatment with the anolyte in the case of microbially induced cystitis, follow-up treatment with catholyte promotes quicker and more complete healing. Similarly, in the case of immunogenic and radiation induced cystitis, treatment with anolyte, in conjunction with treatment with catholyte, will ensure eradication of any opportunistic infectious agents.
Example:
Fifteen patients with chronic progressive Interstitial Cystitis (IC) were treated according to the following protocol.
All patients were admitted for overnight evaluation and an indwelling catheter was inserted into the bladder. The following morning, the freshly generated, mixed oxidant anolyte solution (pH=7, ORP=+750mV) was diluted to a 50% strength with normal saline (0,9% m/v) and 1000ml of the 50% strength solution was infused into the bladder lumen for 6 hours. In patients where the chronic nature of the condition had reduced bladder capacity to less than 1000ml, the maximum volume to accommodate the reduced bladder capacity was administered as an instillation. The mixed oxidant perfusate was subsequently drained from the bladder and flushed with 100ml of sterile saline (0,9% m/v).
Thereafter 1000ml of the mixed predominantly anti-oxidant radical catholyte solution (pH=11 , ORP=-850mV) was infused into the bladder by way of the indwelling catheter for a further six-hour period.
Following drainage of the anti-oxidant solution, and removal of the indwelling catheter, the patients were discharged from the medical facility.
Of the fifteen patients treated to date, no relapse of symptoms of the original condition have occurred and all patients have reported a significant improvement in urine retention capacity, reduced frequency of voluntary bladder emptying, and an extended duration of inter-voiding interval. These significant improvements were achieved without perpetuation of the adjunct antimicrobial and analgesic therapy prescribed for the original condition.
The use of electrochemically activated aqueous solutions as direct infusions or instillations has been shown to offer significant relief or resolution of clinical disease of the urinary bladder and associated anatomical architecture as may be associated with chronic inflammation arising from neurogenic voiding dysfunction, intractable haemorrhagic cystitis secondary to pelvic radiation therapy, and chronic recurrent cystitis of various non-specific microbial and/or inflammatory aetiologies
It will be appreciated that many variations in detail are possible without departing from the scope or spirit of the invention as defined in the claims.

Claims

1. A method of treatment of a human or animal body suffering from acute and/or chronic microbially induced cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution.
2. The method may include the additional step of infusing or instilling the aqueous, mixed reductant, predominantly cation-containing solution into the lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed oxidant, predominantly anion-containing solution.
3. A method of treatment of a human or animal body suffering from acute and/or chronic immunogenic and radiation induced cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed reductant, predominantly cation-containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed reductant, predominantly cation-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between the bladder wall and the solution.
The method may include the additional step of infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of the urinary bladder of the human or animal body after treatment of the same with the aqueous, mixed reductant, predominantly cation-containing solution.
5. A method of treatment of a human or animal body suffering from acute and/or chronic cystitis, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling, at a rate of approximately 150ml/hour, 2 litres of a solution comprising substantially equal parts by volume of the aqueous, mixed reductant, predominantly cation- containing solution and the aqueous, mixed oxidant, predominantly anion- containing solution and diluted to 50% strength with normal saline, into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed solution and the entire bladder mucosal surface so as to ensure maximal contact between the bladder wall and any associated infectious microbial agents, and the solution.
6. The method as claimed in claims 1 to 5 characterised therein that the electrochemically activated, aqueous solution is selected from a group consisting of an anion-containing solution; a cation-containing solution; a mixture of an anion-containing solution and a cation-containing solution; an anion-containing solution having been prepared from an anion-containing solution, a cation- containing solution or a mixture of an anion-containing solution and a cation- containing solution; and a cation-containing solution having been prepared from an anion-containing solution, a cation-containing solution or a mixture of an anion-containing solution and a cation-containing solution.
7. The method as claimed in claims 1 to 5 characterised therein that the electrochemically activated, aqueous solution is prepared by means of electrolysis of an aqueous solution of a salt.
8. The method as claimed in claim 7 characterised therein that the salt is selected from a group consisting of alkali and alkali earth metal chlorides; -carbonates; -bi- carbonates; -phosphates; -sulphates, or -nitrates; for example, sodium chloride; non-iodated sodium chloride; potassium chloride; calcium chloride; sodium carbonate; -bicarbonate; and -phosphate; potassium carbonate; -bicarbonate; and -phosphate; calcium phosphate; sodium-; -potassium; and calcium nitrate; and a mixture of at least two of the aforementioned salts.
9. The method as claimed in claim 7 characterised therein that the electrochemically activated, aqueous solution is produced from an aqueous salt solution having a concentration of between 0.0001 % to 10%, and for some specific systems without pre-dilution of the feed, preferably between about 0.3% and 0.5% aqueous salt solution.
10. The method as claimed in claims 1 to 5 characterised therein that the electrochemically activated, aqueous solution is produced by an electrochemical reactor or electrolysis device having a through flow electro-chemical cell with two co-axial cylindrical electrodes, with a tubular ceramic diaphragm located co- axially between the two electrodes so as to separate an annular inter-electrode space into a co-axial, annular catholytic and an annular anolytic chamber arrangement, wherein the electrochemical cell has a relatively small, annular, cross-sectional total open area for fluid flow, preferably of about 180mm2, for causing turbulent fluid flow there through.
11. The method as claimed in claims 1 to 5 characterised therein that the anolyte and catholyte are produced in the electrochemical cell under a relatively low current of about 5A to 8A, and a relatively high voltage of about 6V to 48V, and more preferably between 8V and 24V.
12. The method as claimed in claims 1 to 5 characterised therein that the mixed oxidant and mixed reductant species of the anolyte and catholyte are labile such that after about 96 hours, the concentration and activity of the various activated species reduce substantially with relatively little, alternatively no active residues remaining.
13. The method as claimed in claims 1 to 5 characterised therein that the anolyte solution has a redox potential of about between +300 mV and +1200 mV, and a pH of between 2 and 8, and preferably a pH of 7; and wherein the catholyte solution has a pH of between 7 and 13, and preferably a pH of about 11.5, and a redox potential of between -200 mV and -1100 mV, and preferably of about -800 mV.
14. The method as claimed in claims 1 to 5 characterised therein that the anolyte solution includes mixed oxidant species such as CIO; CIO"; HCIO; OH"; HO2 "; H2O2; O3; S2O8 2" and CI2O6 2.
15. The method as claimed in claims 1 to 5 characterised therein that the catholyte solution includes mixed reductant species such as OH"; H3 "; O2; H2 ; HO2'; HO2 " and O2 ".
16. The method as claimed in claims 1 to 5 characterised therein that the anolyte contains organic radicals and other components such as Cl2, HCIO, CIO', CIO-,
CI-, HO2, HO2\ O2, HO, O3, O2 , 3O2, O2, O\ H3O+, Cl\ H\ H2O2, CI2O, CIO2 ', HCI,
CI2O7, S2O8 2", C2O6 2", HCIO, H2SO4, and HSO3CI.
17. The method as claimed in claims 1 to 5 characterised therein that the catholyte contains organic radicals and other components such as HO", H3O2 ", O2 ", HO2\
H2O2, H2, HO, H2 ', NaOH, KOH, Ca(OH)2 and Mg(OH)2.
18. The method as claimed in claims 1 to 5 characterised therein that the physical and chemical characteristics, including specific conductivity, redox potential and pH, concentration of activated species and other characteristics of the anolyte and catholyte are adjusted for particular applications by varying levels of saline concentration and the mineral content of the feed water, as well as the operational variables of the electrochemical reactor, including flow rates, flow regimes, -paths and -rates of recycle, currents and potential differences.
19. Use of an aqueous, mixed oxidant, predominantly anion-containing solution in the treatment of acute and chronic microbially induced cystitis, wherein the aqueous, mixed oxidant, predominantly anion-containing solution is infused or instilled into the lumen of a urinary bladder; and wherein maximal contact between infectious microbial agents and the solution is achieved through a process of hydrodistention.
20. Use of an aqueous, mixed oxidant, predominantly anion-containing solution in the preparation of a medicament for use in the treatment of acute and chronic microbially induced cystitis.
21. Use of an aqueous, mixed oxidant, predominantly anion-containing solution in the treatment of acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture.
22. Use of an aqueous, mixed oxidant, predominantly anion-containing solution in the preparation of a medicament for use in the treatment of acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and the associated anatomical architecture.
23. Use of an aqueous, mixed reductant, predominantly cation-containing solution in the treatment of acute and chronic immunogenic and radiation induced cystitis, wherein the aqueous, mixed reductant, predominantly cation-containing solution is infused or instilled into the lumen of a urinary bladder; and wherein maximal contact between infectious microbial agents and the solution is achieved through a process of hydrodistention.
24. Use of an aqueous, mixed reductant, predominantly cation-containing solution in the preparation of a medicament for use in the treatment of acute and chronic immunogenic and radiation induced cystitis.
25. An aqueous, mixed oxidant, predominantly anion-containing solution characterised therein that is possesses distinctive anti-inflammatory properties and is suitable for use either as an instillation or as an infusate for controlling or resolving inflammatory and hyperaesthetic urine voiding symptoms and for reducing or resolving clinical haemorrhagic and histopathologic symptoms associated with repeated radiation therapies.
26. Use of an aqueous, mixed oxidant, predominantly anion-containing solution in controlling or resolving inflammatory and hyperaesthetic urine voiding symptoms and for reducing or resolving clinical haemorrhagic and histopathologic symptoms associated with repeated radiation therapies.
27. A method of treatment of a human or animal body suffering from acute and/or chronic, superficial and/or interstitial, infectious and/or inflammatory conditions of the urinary bladder and its associated anatomical architecture, the method including the steps of electrochemically activating a dilute aqueous solution such that the electrochemically activated, aqueous solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed reductant, predominantly cation-containing solution; separating the aqueous, mixed oxidant, predominantly anion-containing solution from the aqueous, mixed reductant, predominantly cation-containing solution; infusing or instilling the aqueous, mixed oxidant, predominantly anion-containing solution into lumen of a urinary bladder of the human or animal body; and through a process of hydrodistention optimising contact between the infused or instilled aqueous, mixed oxidant, predominantly anion-containing solution and the entire bladder mucosal surface so as to ensure maximal contact between infectious microbial agents and the solution.
28. A method of treatment of a human or animal body substantially as herein exemplified with reference to the accompanying examples.
PCT/ZA2002/000197 2001-12-10 2002-12-09 Electrochemically activated water for the treatment of cystitis WO2003050044A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002351430A AU2002351430A1 (en) 2001-12-10 2002-12-09 Electrochemically activated water for the treatment of cystitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA2001/10119 2001-12-10
ZA200110119 2001-12-10

Publications (1)

Publication Number Publication Date
WO2003050044A1 true WO2003050044A1 (en) 2003-06-19

Family

ID=25589401

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ZA2002/000197 WO2003050044A1 (en) 2001-12-10 2002-12-09 Electrochemically activated water for the treatment of cystitis

Country Status (3)

Country Link
AU (1) AU2002351430A1 (en)
WO (1) WO2003050044A1 (en)
ZA (1) ZA200404611B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006103314A1 (en) * 2005-03-30 2006-10-05 Oy Keskuslaboratorio-Centrallaboratorium Ab Electrochemical method for preparing microbiocidal solutions
EP1826183A1 (en) * 2006-02-24 2007-08-29 Kimihiro Sato Ionized water and method of producing same
US7618655B2 (en) * 2003-11-21 2009-11-17 Cytotools Gmbh Method for the preparation of aqueous solutions of reactive chlorine compounds
US8137730B2 (en) 2007-12-21 2012-03-20 Sun-Maid Growers Of California Power spraying of agricultural products with wrinkled skins
RU2452535C1 (en) * 2010-09-29 2012-06-10 Федеральное государственное учреждение "Новосибирский научно-исследовательский институт туберкулеза" Министерства здравоохранения и социального развития Российской Федерации Method of treating chronic cystitis
US9089511B2 (en) 2008-07-25 2015-07-28 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
RU2593889C1 (en) * 2015-04-28 2016-08-10 Тимур Асланбекович Гяургиев Method for integrated treatment of chronic bacterial recurrent cystitis in females at aggravation stage
US9572810B2 (en) 2010-07-22 2017-02-21 Reven Pharmaceuticals, Inc. Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution
EP3593862A1 (en) * 2018-07-12 2020-01-15 Azad Pharma AG Electrochemically activated salt solution

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0792584A1 (en) * 1994-07-29 1997-09-03 Toto Ltd. Strongly acidic sterile water containing low-concentration hypochlorous acid, method of forming strongly acidic sterile water containing low-concentration hypochlorous acid, apparatus therefor, and apparatus for forming and delivering strongly acidic sterile water containing low-concentration hypoch
US5731008A (en) * 1990-05-23 1998-03-24 Medical Discoveries, Inc. Electrically hydrolyzed salines as microbicides
WO1999020287A1 (en) * 1997-10-23 1999-04-29 Radical Waters Ip (Pty) Ltd The use of an aqueous solution in the preparation of a medicament for use in the treatment of live animals
WO1999020286A1 (en) * 1997-10-23 1999-04-29 Radical Waters Ip (Pty) Ltd A composition for the treatment of legionella pneumophila and a method for such treatment
JPH11209292A (en) * 1998-01-22 1999-08-03 Morinaga Milk Ind Co Ltd Therapeutic agent for dermatosis
RU2138270C1 (en) * 1996-05-06 1999-09-27 Басалаева Надежда Львовна Method of prophylaxis of postabortive endometritis
WO2001054704A1 (en) * 2000-01-12 2001-08-02 Novacal Pharmaceuticals, Llc Physiologically balanced, ionized, acidic solution and methodology for use in wound healing
RU2195970C2 (en) * 2000-05-24 2003-01-10 Ханты-Мансийский государственный медицинский институт Method for draining and healing intracavitary pathological focus

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731008A (en) * 1990-05-23 1998-03-24 Medical Discoveries, Inc. Electrically hydrolyzed salines as microbicides
EP0792584A1 (en) * 1994-07-29 1997-09-03 Toto Ltd. Strongly acidic sterile water containing low-concentration hypochlorous acid, method of forming strongly acidic sterile water containing low-concentration hypochlorous acid, apparatus therefor, and apparatus for forming and delivering strongly acidic sterile water containing low-concentration hypoch
RU2138270C1 (en) * 1996-05-06 1999-09-27 Басалаева Надежда Львовна Method of prophylaxis of postabortive endometritis
WO1999020287A1 (en) * 1997-10-23 1999-04-29 Radical Waters Ip (Pty) Ltd The use of an aqueous solution in the preparation of a medicament for use in the treatment of live animals
WO1999020286A1 (en) * 1997-10-23 1999-04-29 Radical Waters Ip (Pty) Ltd A composition for the treatment of legionella pneumophila and a method for such treatment
JPH11209292A (en) * 1998-01-22 1999-08-03 Morinaga Milk Ind Co Ltd Therapeutic agent for dermatosis
WO2001054704A1 (en) * 2000-01-12 2001-08-02 Novacal Pharmaceuticals, Llc Physiologically balanced, ionized, acidic solution and methodology for use in wound healing
RU2195970C2 (en) * 2000-05-24 2003-01-10 Ханты-Мансийский государственный медицинский институт Method for draining and healing intracavitary pathological focus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199942, Derwent World Patents Index; Class B06, AN 1999-497074, XP002235492 *
DATABASE WPI Section Ch Week 200038, Derwent World Patents Index; Class B06, AN 2000-440110, XP002235494 *
DATABASE WPI Section PQ Week 200318, Derwent World Patents Index; Class P34, AN 2003-181797, XP002235493 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8728537B2 (en) 2003-11-21 2014-05-20 Cytotools Ag Compositions for improvement of wound healing
US7618655B2 (en) * 2003-11-21 2009-11-17 Cytotools Gmbh Method for the preparation of aqueous solutions of reactive chlorine compounds
US8349369B2 (en) 2003-11-21 2013-01-08 Cytotools Gmbh Method and pharmaceutical composition for improvement of wound healing
WO2006103314A1 (en) * 2005-03-30 2006-10-05 Oy Keskuslaboratorio-Centrallaboratorium Ab Electrochemical method for preparing microbiocidal solutions
EP1826183A1 (en) * 2006-02-24 2007-08-29 Kimihiro Sato Ionized water and method of producing same
EP2228346A1 (en) * 2006-02-24 2010-09-15 Skyview Enterprises Ionized water and method of producing same
US8137730B2 (en) 2007-12-21 2012-03-20 Sun-Maid Growers Of California Power spraying of agricultural products with wrinkled skins
US9089511B2 (en) 2008-07-25 2015-07-28 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US9089602B2 (en) 2008-07-25 2015-07-28 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US9775798B2 (en) 2008-07-25 2017-10-03 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US11110053B2 (en) 2008-07-25 2021-09-07 Reven Pharmaceuticals Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
US9572810B2 (en) 2010-07-22 2017-02-21 Reven Pharmaceuticals, Inc. Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution
US9867849B2 (en) 2010-07-22 2018-01-16 Reven Pharmaceuticals, Inc. Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution
US11202798B2 (en) 2010-07-22 2021-12-21 Reven Pharmaceuticals, Inc. Method of treating or ameliorating skin conditions with a magnetic dipole stabilized solution
RU2452535C1 (en) * 2010-09-29 2012-06-10 Федеральное государственное учреждение "Новосибирский научно-исследовательский институт туберкулеза" Министерства здравоохранения и социального развития Российской Федерации Method of treating chronic cystitis
RU2593889C1 (en) * 2015-04-28 2016-08-10 Тимур Асланбекович Гяургиев Method for integrated treatment of chronic bacterial recurrent cystitis in females at aggravation stage
EP3593862A1 (en) * 2018-07-12 2020-01-15 Azad Pharma AG Electrochemically activated salt solution
WO2020011870A1 (en) * 2018-07-12 2020-01-16 Azad Pharma Ag Electrochemically activated salt solution

Also Published As

Publication number Publication date
AU2002351430A1 (en) 2003-06-23
ZA200404611B (en) 2010-08-25

Similar Documents

Publication Publication Date Title
US5079010A (en) Pharmaceutical preparation for the treatment of wounds, damaged tissue and inflammation in animals
US6197814B1 (en) Disinfectant and method of making
US6258249B1 (en) Sterilization of surgical sites
WO2003050044A1 (en) Electrochemically activated water for the treatment of cystitis
WO2001054704A1 (en) Physiologically balanced, ionized, acidic solution and methodology for use in wound healing
Inoue et al. Trial of electrolyzed strong acid aqueous solution lavage in the treatment of peritonitis and intraperitoneal abscess
JP2003520820A5 (en)
EP1221980B1 (en) Electrolytic generation of iodine for preventing implant induced infections
CN104958830B (en) A kind of anti-infective therapy of subacidity electrolyzed oxidizing water gynaecology equipment
JP2004530659A (en) Methods and formulations for antitumor and antimetastatic effects
US5222936A (en) Intracorporeal iontophoretic method
CN103008683A (en) Preparation method for high-efficient monomer silver solution as well as high-efficient monomer silver gel and lotion
CN113398334A (en) Carbon quantum dot hydrogel composite scaffold material, preparation method and application
JPH07185550A (en) Electrolytically formed water
CN108926577A (en) A kind of method that electric potential water is used for Wound antibiotic healing cleaning-nursing
WO2023125763A1 (en) Povidone iodine-containing temperature-sensitive gelling preparation
RU2422377C2 (en) Biocidal concentrate
JPH0710762A (en) Gargle for stomatitis
CN110354390A (en) A kind of diabetes Wound healing preparation and its application
CN100393633C (en) Aquatic raising waste water sterilizing method
Pompeius et al. A successfully treated case of condyloma acuminatum of the urethra and urinary bladder
CN1281271C (en) Biological bacteria inhibitor
JPH07258099A (en) Apparatus for producing cleaning liquid and cleaning liquid produced thereby
WO2023018767A1 (en) Antimicrobial bladder additives system and method
Cole Physiology of the Human Ureter

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200404611

Country of ref document: ZA

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP